Cellectis SA (CLLS)
2.62
-0.03
(-1.13%)
USD |
NASDAQ |
Apr 23, 11:32
Cellectis Revenue (TTM): 16.50M for Sept. 30, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2023 | 16.50M |
| June 30, 2023 | 16.52M |
| March 31, 2023 | 17.64M |
| December 31, 2022 | 19.17M |
| September 30, 2022 | -11.59M |
| June 30, 2022 | -3.459M |
| March 31, 2022 | 6.411M |
| December 31, 2021 | 30.35M |
| September 30, 2021 | 36.11M |
| June 30, 2021 | 33.98M |
| March 31, 2021 | 25.70M |
| December 31, 2020 | 50.23M |
| September 30, 2020 | 63.64M |
| June 30, 2020 | 65.95M |
| March 31, 2020 | 64.20M |
| December 31, 2019 | 15.11M |
| Date | Value |
|---|---|
| September 30, 2019 | 11.54M |
| June 30, 2019 | 3.962M |
| March 31, 2019 | 7.859M |
| December 31, 2018 | 12.86M |
| September 30, 2018 | 17.77M |
| June 30, 2018 | 22.98M |
| March 31, 2018 | 24.43M |
| December 31, 2017 | 25.13M |
| September 30, 2017 | 27.46M |
| June 30, 2017 | 32.60M |
| March 31, 2017 | 43.71M |
| December 31, 2016 | 44.88M |
| September 30, 2016 | 66.36M |
| June 30, 2016 | 63.64M |
| March 31, 2016 | 54.26M |
| December 31, 2015 | 55.48M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
-11.59M
Minimum
Sep 2022
65.95M
Maximum
Jun 2020
25.66M
Average
18.41M
Median
Revenue (TTM) Benchmarks
| DBV Technologies SA | -- |
| Biophytis SA | -- |
| Genfit SA | 30.01M |
| Edap TMS SA | 65.36M |
| Biodexa Pharmaceuticals Plc | 0.4761M |